CN117298116A — 盐酸佐利替尼制剂
Assigned to Jiangsu Chentai Pharmaceutical Technology Co ltd · Expires 2023-12-29 · 2y expired
What this patent protects
本发明涉及一种盐酸佐利替尼组合物。所述组合物包括:15~30重量份的盐酸佐利替尼,50~85重量份的填充剂,1~10重量份的崩解剂,0.01~2重量份的助流剂,0.5~5重量份的润滑剂;所述盐酸佐利替尼在所述组合物中的重量百分比为15%~30%。本发明的组合物的含量、含量均匀度、有关物质、崩解时限和溶出度均正常,且工艺及质量稳定性高,可用于预防或治疗肿瘤或癌症,例如非小细胞肺癌。
USPTO Abstract
本发明涉及一种盐酸佐利替尼组合物。所述组合物包括:15~30重量份的盐酸佐利替尼,50~85重量份的填充剂,1~10重量份的崩解剂,0.01~2重量份的助流剂,0.5~5重量份的润滑剂;所述盐酸佐利替尼在所述组合物中的重量百分比为15%~30%。本发明的组合物的含量、含量均匀度、有关物质、崩解时限和溶出度均正常,且工艺及质量稳定性高,可用于预防或治疗肿瘤或癌症,例如非小细胞肺癌。
Drugs covered by this patent
- Retevmo (SELPERCATINIB) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.